After 25 years of research, Brazilian scientists have introduced polylaminin, the world’s first drug that claims to regenerate spinal cord injuries, offering hope for millions living with paralysis.
Developed by Tatiana Coelho de Sampaio and her team at the Federal University of Rio de Janeiro, polylaminin is derived from the placental laminin protein and is injected directly into the spine.
Early experimental trials involving patients with paraplegia and quadriplegia due to spinal cord ruptures have shown remarkable results. Several patients reportedly experienced full recovery, regaining mobility without lasting side effects. The drug has demonstrated the ability to regrow nerve fibers and reduce inflammation, which contributes to its positive effect on motor function recovery.
These findings build on previous animal studies where polylaminin improved locomotion after spinal cord injury by promoting neuron regrowth and playing an anti-inflammatory role.
While the prospects are groundbreaking, the treatment still awaits peer-reviewed validation and regulatory approval before it can be widely recommended.
If confirmed, polylaminin could transform treatment paradigms worldwide, providing a medical option for spinal cord injury patients that was once considered impossible. The discovery underscores Brazil’s potential in biomedical innovation, supported by collaboration with Cristália Laboratory.
This breakthrough marks a hopeful step forward in regenerative medicine, pending further large-scale human trials and formal endorsements from the scientific community and regulatory bodies.
